Collectively, our data provide a rationale for combination immunotherapy involving immune effector cell (IL-15-activated natural killer cells) and target cell (HDI) manipulation in first- and/or second-line treatment regimens for Ewing sarcoma. The gene discussed is IL15; the disease is Ewing sarcoma.